B. Riley Securities Reiterates Rating on ELTX $ELTX
Key Points
- B. Riley Securities now rates Elicio Therapeutics, Inc. ($ELTX) "buy" with a $27 target.
- B. Riley Securities's $27 price target implies 81.82% upside from Elicio Therapeutics, Inc.'s ($ELTX) current $14.85 share price.
- The Street's average $ELTX price target is $16.50 (Strong Buy).
- $ELTX last traded around $14.85.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
B. Riley Securities reiterated its rating on Elicio Therapeutics, Inc. ($ELTX) to a "buy" rating in a recent research note and set a price target of $27, a 81.82% upside from the current price.
Elicio Therapeutics, Inc. Stock Up 422.9%
Shares of Elicio Therapeutics, Inc. ($ELTX) traded around $14.85 on Saturday, up 422.9% for the day.
Elicio Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Elicio Therapeutics, Inc.
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Get Elicio Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ELTX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.